Bristol Myers Squibb (CELG-RI) Amortization - Intangibles (2019 - 2026)

Bristol Myers Squibb (CELG-RI) posted quarterly Amortization - Intangibles of $437.0 million for Q1 2026, down 47.35% YoY from $830.0 million in Q1 2025, and down 47.09% sequentially from $826.0 million in Q4 2025.

Bristol Myers Squibb (CELG-RI) Amortization - Intangibles (2019 - 2026) Analysis & Trends

Bristol Myers Squibb has disclosed Amortization - Intangibles across 8 years of filings, most recently posting $437.0 million for Q1 2026.

  • In Q1 2026, Amortization - Intangibles fell 47.35% year-over-year to $437.0 million; the TTM figure through Mar 2026 stood at $2.9 billion (down 60.19% YoY), while the FY2025 annual figure was $3.3 billion, down 62.61% from the prior year.
  • Amortization - Intangibles fell to $437.0 million in Q1 2026, from $826.0 million in the prior quarter.
  • Over the last five years, Amortization - Intangibles for CELG-RI reached as high as $2.4 billion in Q3 2022 and fell as low as $437.0 million in Q1 2026.
  • The 5-year median for Amortization - Intangibles is $2.3 billion (2023), against an average of $1.8 billion.
  • Annual changes were most pronounced in 2024 — Amortization - Intangibles rose 7.04% — and 2025, when it plunged 65.65%.
  • A 5-year view of Amortization - Intangibles shows it stood at $2.3 billion in 2022, then dropped by 2.77% to $2.3 billion in 2023, then slipped by 25.68% to $1.7 billion in 2024, then slumped by 51.21% to $826.0 million in 2025, then slumped by 47.09% to $437.0 million in 2026.
  • According to Business Quant data, Amortization - Intangibles over the past three periods registered $437.0 million, $826.0 million, and $831.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 437.00 Mn
Dec 31, 2025 826.00 Mn
Sep 30, 2025 831.00 Mn
Jun 30, 2025 830.00 Mn
Mar 31, 2025 830.00 Mn
Dec 31, 2024 1.69 Bn
Sep 30, 2024 2.41 Bn
Jun 30, 2024 2.42 Bn
Mar 31, 2024 2.36 Bn
Dec 31, 2023 2.28 Bn
Sep 30, 2023 2.26 Bn
Jun 30, 2023 2.26 Bn
Mar 31, 2023 2.26 Bn
Dec 31, 2022 2.34 Bn
Sep 30, 2022 2.42 Bn
Jun 30, 2022 2.42 Bn
Mar 31, 2022 2.42 Bn
Dec 31, 2021 2.42 Bn
Sep 30, 2021 2.55 Bn
Jun 30, 2021 2.55 Bn